3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
145
Parkinson Disease 4, Autosomal Dominant Lewy Body
120
Melanoma
84
Squamous Cell Carcinoma of Head and Neck
56
Neoplasms
44
Breast Neoplasms
41
Stomach Neoplasms
38
Colorectal Neoplasms
38
Triple Negative Breast Neoplasms
37
Neoplasm Metastasis
36
Carcinoma, Renal Cell
36
Ovarian Neoplasms
30
Lung Neoplasms
30
Head and Neck Neoplasms
29
Urinary Bladder Neoplasms
28
Carcinoma, Transitional Cell
26
Carcinoma, Hepatocellular
26
Pancreatic Neoplasms
23
Esophageal Neoplasms
20
Endometrial Neoplasms
16
Recurrence
15
Prostatic Neoplasms
15
Multiple Myeloma
15
Fallopian Tube Neoplasms
15
Carcinoma
14
Sarcoma
13
Lymphoma, Large B-Cell, Diffuse
13
Small Cell Lung Carcinoma
12
Lymphoma, Follicular
12
Lymphoma, Non-Hodgkin
11
Interventions
Ipilimumab
10
tremelimumab
6
durvalumab
5
Nivolumab
3
pembrolizumab
2
tilsotolimod
1
spartalizumab
1
relatlimab
1
folfirinox
1
balstilimab
1
Vemurafenib
1
Vaccines
1
Radiotherapy
1
Radiofrequency Ablation
1
Radiation
1
Paclitaxel
1
Oxaliplatin
1
Opdualag
1
Melphalan
1
Leucovorin
1
Fluorouracil
1
Docetaxel
1
Cryosurgery
1
Carboplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Diabetes Mellitus, Insulin-Dependent, 12
×
pembrolizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts
NCT03302234
2023-09-26
KEYNOTE-598
Merck Sharp & Dohme LLC
Phase 3
Completed
568 enrolled
20 charts